BUNIA, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The World Health Organization reported that 80% of recent Ebola cases in eastern Congo stem from unidentified transmission routes. Many patients were not listed on contact tracing records prior to testing confirming their infections. This gap hampers early isolation efforts and delays treatment for symptomatic individuals. Response teams frequently identify new clusters only after patients present at clinics or succumb within their communities. The ongoing outbreak involves the less common Bundibugyo virus strain.
As of July 13, Congo has documented 2,011 confirmed cases with 754 fatalities. The province of Ituri remains the primary hotspot, with 1,808 cases and 631 deaths. North Kivu reported 182 cases and 106 deaths. Other affected regions include South Kivu, Haut-Uele, and Tshopo. Authorities have placed 753 patients under isolation and recorded 366 recoveries. Around 67% of identified contacts in the most affected provinces are being monitored by response teams.
Contact tracing is vital for health workers to identify and isolate exposed individuals before further transmission occurs. Typically, contacts are observed for 21 days following their last known exposure. WHO noted that 92.3% of 430 investigated deaths up to July 5 happened outside healthcare facilities or before hospital admission, limiting timely testing and isolation opportunities. Ebola transmits through direct contact with infected blood or bodily fluids, and contaminated objects can also act as vectors.
Confirmed cases span five provinces
The outbreak has affected 45 health zones across five provinces in Congo. In Ituri, cases have been reported in 26 zones, while North Kivu has 11 infected zones. Haut-Uele has 14 cases with 13 deaths, Tshopo has four cases with three deaths, and South Kivu has three cases with one death. The wide geographic distribution has increased the burden on laboratories, treatment facilities, and mobile surveillance teams.
In Uganda, 20 cases and two deaths were confirmed by July 14. Seventeen patients had recovered, with the latest case confirmed on June 21. Fifteen of these infections were linked to travel from Congo, while five cases were associated with local transmission events. Ugandan authorities reported no documented community spread and monitored travelers and aid workers leaving affected zones during the outbreak period.
Expansion of testing and clinical interventions
There is currently no licensed vaccine or approved specific treatment for Bundibugyo virus. Medical teams focus on supportive care including fluids, oxygen, electrolyte replacement, and other symptomatic treatments. WHO announced on July 2 that the first molecular diagnostic test for the virus was added to its Emergency Use Listing. Presently, ten laboratories are conducting testing across the affected regions, with a combined capacity of over 2,000 tests daily. Additionally, a clinical trial involving remdesivir and the monoclonal antibody therapy MBP134 has been initiated.
The government of Congo, WHO, and Africa CDC continue to coordinate efforts on surveillance, testing, treatment, safe burials, and community outreach. Challenges such as insecurity, displacement, frequent movement in mining areas, and strikes among health workers have hampered response efforts. WHO has received approximately 40% of its $115 million funding appeal. Authorities emphasize the importance of faster case detection, as most new infections occur outside known transmission chains.